Abstract: Disclosed herein are an emergency operating system and an emergency operating method for a hybrid vehicle with a damaged bearing of an engine, which are capable of preventing a bearing from being further damaged due to a drive motor and a hybrid starter and generator (HSG) when damage to the bearing installed in an engine is detected and capable of driving the hybrid vehicle and which include a bearing damage detection operation, an engine driving maintaining operation, a first state of charge (SOC) comparison operation, and a first emergency operating operation.

Abstract: The present invention relates to a composition comprising a bilberry extract as an active ingredient for preventing or treating sensorineural hearing impairment. The bilberry extract was found to exhibit effects of inhibiting the apoptosis of auditory cells in which sensorineural damage has been induced by neomycin and increasing a reduced number of hair cells in juvenile zebra fishes such that the composition comprising the bilberry extract as an active ingredient can be provided as a pharmaceutical composition and a health food for preventing or treating various hearing impairments induced by sensorineural damage.

Abstract: A method for sensing damage to a bearing of an engine using a vibration signal may sense the damage to the bearing even without a sensor for directly sensing the damage to the bearing using a frequency signal input to a knocking sensor from the engine for each traveling state (acceleration traveling, cruise traveling, deceleration traveling) of a vehicle.

Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

Abstract: A method for sensing damage to a bearing of an engine using a vibration signal may sense the damage to the bearing even without a sensor for directly sensing the damage to the bearing using a frequency signal input to a knocking sensor from the engine for each traveling state (acceleration traveling, cruise traveling, deceleration traveling) of a vehicle.

Abstract: The present invention relates to a medical dressing and a manufacturing method, and to a medical dressing and a manufacturing method therefor, the medical dressing comprising: a lower support film; a release film; and an adhesive sheet part (110) for application, which is placed on the release film (200) and is attached to the skin, wherein the release film (200) consists of a release film part (210) for fixing and a separable release film part (220) to be separated therefrom by a cutting line (211) formed on the release film part (210) for fixing, so that a predetermined region of the separable release film part is positioned to overlap with the bottom surface of the adhesive sheet part (110), thereby allowing, during separation of the separable release film part (220) from the release film part (210) for fixing, separation together with the adhesive sheet part (110) for application, and the area of the separable release film part (220), which overlaps with the bottom surface of the adhesive sheet part (110)

Abstract: Provided is a sustained-release lipid pre-concentrate in the form of a lipid solution, including an unsaturated fatty acid having 14 to 20 carbon atoms (C14˜C20); a phospholipid; and ?-tocopherol acetate, wherein the sustained-release lipid pre-concentrate is free of diacyl glycerol and sorbitan unsaturated fatty acid ester; and forms a liquid crystal in an aqueous medium. Further provided is a sustained-release injectable pharmaceutical composition in the form of a lipid solution, including the pre-concentrate and a pharmacologically active substance, wherein the sustained-release injectable pharmaceutical composition is free of diacyl glycerol and sorbitan unsaturated fatty acid ester.

Abstract: Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.

Abstract: Provided are a semiconductor device and a method for fabricating the same. The semiconductor device includes an active fin protruding upwardly from a substrate and extending in a first direction and a gate structure extending in a second direction intersecting to cross the active fin, where a first width of a lower portion of the gate structure that contacts the active fin is greater than a second width of the lower portion of the gate structure that is spaced apart from the active fin.

Abstract: A composition for preventing or treating hearing loss, containing a Vitis vinifera leaf extract as an active ingredient, is disclosed. A pharmaceutical composition for preventing or treating hearing loss, containing the extract (a Vitis vinifera leaf extract) as an active ingredient, protects auditory hair cells in the cochlea and spiral ganglion cells from damage caused by noise and the like and effectively reduces the hearing threshold measured in the auditory nerves, thereby being usable as an agent for preventing or treating hearing loss.

Abstract: The present invention relates to a combination formulation containing metformin for treating non-insulin-dependent diabetes and an HMG-CoA reductase inhibitor for treating dyslipidemia. The present invention provides a combination formulation and a method for preparing the combination formulation, wherein the combination formulation contains metformin and an HMG-CoA reductase inhibitor.

Abstract: Provided is a method of preventing and treating a dry eye syndrome comprising administering a pharmaceutical composition comprising sulglycotide or its pharmaceutically acceptable salt as an active ingredient.

Abstract: An electronic device is provided. The electronic device includes a power receiver (PRx) that includes a receiver coil for receiving a power signal from a wireless power transmitting device and a wireless charging integrated circuit (IC) for converting the power signal into electrical energy, a power management circuit that is electrically connected to the PRx and configured to charge a battery using the electrical energy, and a processor that is electrically connected with the PRx and the power management circuit. The processor activates a power hold mode (PHM) if a charging level of the battery is a fully charged level and controls auxiliary charging of the battery.

Abstract: Provided is a composition for preventing and treating a menopausal disorder containing extracts of Dendropanax morbifera LEV. as an active ingredient. Specifically, the extracts of Dendropanax morbifera LEV. exhibit a significant ER agonist activity within a cell, and exhibit a very potent ER agonist (full agonist) activity with an EC50 value of about 100 ?g/ml. Thus, the extracts of Dendropanax morbifera LEV. comprising a high content of plant metabolites similar to estrogen can be useful as hormone replacement therapy capable of improving various symptoms derived from a deficiency of estrogen in menopausal women.

Abstract: The present invention relates to a pharmaceutical composition, containing sarpogrelate or a pharmaceutically acceptable salt thereof as an active ingredient, for preventing, alleviating, or treating sensorineural hearing loss. The sarporgrelate according to the present invention protects against hearing loss caused by noise through the suppression of auditory cell apoptosis and the expression increase of antioxidant enzyme in auditory cells, and thus can be advantageously used in the prevention and alleviation of sensorineural hearing loss.

Abstract: An electronic device is provided. The electronic device includes a power receiver (PRx) that includes a receiver coil for receiving a power signal from a wireless power transmitting device and a wireless charging integrated circuit (IC) for converting the power signal into electrical energy, a power management circuit that is electrically connected to the PRx and configured to charge a battery using the electrical energy, and a processor that is electrically connected with the PRx and the power management circuit. The processor activates a power hold mode (PHM) if a charging level of the battery is a fully charged level and controls auxiliary charging of the battery.

Abstract: A surveillance server connected to a camera through a network is provided, the camera acquiring an image of a surveillance area. The surveillance server includes: a data acquisition unit configured to acquire from the camera image data of the image that is encrypted; a mode selection unit configured to select a processing mode of the image data; and a decryption control unit configured to decrypt the image data in response to selection of a first mode.

Abstract: The present invention relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, which improves the stability of dutasteride, which is a poorly soluble drug as a 5-alpha reductase inhibitor, and a process for its preparation. More particularly, the present invention also relates to a capsule formulation which is smaller in size than a commercial dutasteride capsule formulation (AVODART®), but has the equivalent dissolution rate by preparing a pharmaceutical composition comprising propylene glycol monolaurate and dutasteride, which can improve the stability of the dutasteride. A dutasteride formulation having enhanced patient's compliance and improved stability and a method for producing the same are provided.

Abstract: The present disclosure relates to a pharmaceutical composition comprising dutasteride and propylene glycol monolaurate, and a capsule formulation comprising the same.

Abstract: Provided is a method of preventing and treating a dry eye syndrome comprising administering a pharmaceutical composition comprising sulglycotide or its pharmaceutically acceptable salt as an active ingredient.